The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Pragmatic Clinical Trial
Treating Rhythmic and Periodic EEG Patterns in Comatose Survivors of Cardiac Arrest.
Whether the treatment of rhythmic and periodic electroencephalographic (EEG) patterns in comatose survivors of cardiac arrest improves outcomes is uncertain. ⋯ In comatose survivors of cardiac arrest, the incidence of a poor neurologic outcome at 3 months did not differ significantly between a strategy of suppressing rhythmic and periodic EEG activity with the use of antiseizure medication for at least 48 hours plus standard care and standard care alone. (Funded by the Dutch Epilepsy Foundation; TELSTAR ClinicalTrials.gov number, NCT02056236.).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines. ⋯ Tisagenlecleucel was not superior to standard salvage therapy in this trial. Additional studies are needed to assess which patients may obtain the most benefit from each approach. (Funded by Novartis; BELINDA ClinicalTrials.gov number, NCT03570892.).
-
Randomized Controlled Trial Multicenter Study
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. ⋯ Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).
-
Randomized Controlled Trial
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein. ⋯ All EDP-938 regimens were superior to placebo with regard to lowering of the viral load, total symptom scores, and mucus weight without apparent safety concerns. (ClinicalTrials.gov number, NCT03691623.).
-
Randomized Controlled Trial Multicenter Study
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Nuvaxoid is safe and 90% effective against the Alpha (B.1.1.7) SARS-CoV-2 variant.
pearl